{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:10Z","timestamp":1787785750900,"version":"build-2784847793"},"reference-count":81,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union NextGenerationEU procedure","award":["#BG-RRP-2.004-0003-C01"],"award-info":[{"award-number":["#BG-RRP-2.004-0003-C01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age, often requiring complex pharmacological management. The heterogeneity of the syndrome and the use of on- and off-label therapeutic agents\u2014ranging from insulin sensitizers and ovulation inducers to oral contraceptives and herbal supplements\u2014pose significant challenges, including adverse effects, drug interactions, and poor adherence. This narrative review explores the role of pharmacists in identifying and mitigating drug-related problems (DRPs) associated with PCOS therapy. Through thematic synthesis of the current literature, the study highlights common DRPs such as suboptimal drug selection, inappropriate dosing, prolonged therapy duration, and treatment-related safety concerns. It underscores the value of pharmacists\u2019 interventions in enhancing medication adherence, optimizing therapeutic regimens, providing patient education, and monitoring adverse events. A structured, patient-level pharmaceutical care model is proposed, emphasizing personalized assessment, interdisciplinary collaboration, and continuous follow-up. The integration of clinical pharmacists into PCOS care teams has the potential to improve treatment effectiveness, patient satisfaction, and long-term health outcomes. Pharmacists\u2019 contributions are especially critical given the widespread use of off-label therapies and supplements with variable evidence of benefit. Tailored pharmaceutical care can thus bridge the existing gaps in PCOS management and enhance the quality of life for the affected individuals.<\/jats:p>","DOI":"10.3390\/pharmacy13040095","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T15:19:31Z","timestamp":1752247171000},"page":"95","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-6965","authenticated-orcid":false,"given":"Hristina","family":"Lebanova","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesselina","family":"Yanachkova","sequence":"additional","affiliation":[{"name":"Research Institute, Medical University-Pleven, 5800 Pleven, Bulgaria"},{"name":"Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynecology Dr. Shterev, 1330 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-5674","authenticated-orcid":false,"given":"Svetoslav","family":"Stoev","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00404-024-07607-x","article-title":"Global Prevalence of Polycystic Ovary Syndrome in Women Worldwide: A Comprehensive Systematic Review and Meta-Analysis","volume":"310","author":"Salari","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2004). Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. Fertil. Steril., 81, 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Christ, J.P., and Cedars, M.I. (2023). Current Guidelines for Diagnosing PCOS. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061113"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1179558119874042","DOI":"10.1177\/1179558119874042","article-title":"Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies","volume":"13","author":"Barber","year":"2019","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7570\/jomes24035","article-title":"Obesity and Polycystic Ovary Syndrome","volume":"33","author":"Kim","year":"2024","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","article-title":"Metabolic Dysfunction in Polycystic Ovary Syndrome: Pathogenic Role of Androgen Excess and Potential Therapeutic Strategies","volume":"35","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2337\/db11-1360","article-title":"Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes","volume":"61","author":"Gambineri","year":"2012","journal-title":"Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coemr.2020.03.004","article-title":"Polycystic Ovary Syndrome Phenotypes and Prevalence: Differential Impact of Diagnostic Criteria and Clinical versus Unselected Population","volume":"12","author":"Mumusoglu","year":"2020","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/ijem.IJEM_30_19","article-title":"Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and Their Response to Clomiphene","volume":"23","author":"Sachdeva","year":"2019","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Espinosa, M.E., S\u00e1nchez, R., Otzen, T., Bautista-Valarezo, E., Aguiar, S., Corrales-Gutierrez, I., Leon-Larios, F., and Manterola, C. (2024). Phenotypic Characterization of Patients with Polycystic Ovary Syndrome in a Population from the Ecuadorian Andes: A Cross-Sectional Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082376"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"176119","DOI":"10.1016\/j.ejphar.2023.176119","article-title":"Promising Drug Candidates for the Treatment of Polycystic Ovary Syndrome (PCOS) as Alternatives to the Classical Medication Metformin","volume":"960","author":"Anbar","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1210\/js.2019-00078","article-title":"Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls","volume":"3","author":"Witchel","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tjog.2021.11.009","article-title":"Polycystic Ovarian Syndrome-Current Pharmacotherapy and Clinical Implications","volume":"61","author":"Rashid","year":"2022","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14656566.2022.2108702","article-title":"Current and Emerging Drug Treatment Strategies for Polycystic Ovary Syndrome","volume":"24","author":"Helvaci","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_17","unstructured":"(2025, March 15). PCNE The PCNE Classification V 9.1 2020. Available online: https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rajiah, K., Sivarasa, S., and Maharajan, M.K. (2021). Impact of Pharmacists\u2019 Interventions and Patients\u2019 Decision on Health Outcomes in Terms of Medication Adherence and Quality Use of Medicines among Patients Attending Community Pharmacies: A Systematic Review. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094392"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ahmed, A., Saqlain, M., Tanveer, M., Blebil, A.Q., Dujaili, J.A., and Hasan, S.S. (2021). The Impact of Clinical Pharmacist Services on Patient Health Outcomes in Pakistan: A Systematic Review. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-06897-0"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1002\/ehf2.13508","article-title":"The Evidence for Pharmacist Care in Outpatients with Heart Failure: A Systematic Review and Meta-Analysis","volume":"8","author":"Schumacher","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Stuhec, M., and Tement, V. (2021). Positive Evidence for Clinical Pharmacist Interventions during Interdisciplinary Rounding at a Psychiatric Hospital. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-92909-2"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ajhp\/zxad133","article-title":"Role and Impact of a Clinical Pharmacist in an Ambulatory Reproductive Endocrinology and Infertility Clinic","volume":"80","author":"Coons","year":"2023","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","article-title":"Writing Narrative Style Literature Reviews","volume":"24","author":"Ferrari","year":"2015","journal-title":"Med. Writ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cen.12784","article-title":"Clinical Characteristics of Polycystic Ovary Syndrome: Investigating Differences in White and South Asian Women","volume":"83","author":"Mani","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1210\/clinem\/dgab232","article-title":"Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study","volume":"106","author":"Fisher","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Palomba, S., Seminara, G., Tomei, F., Marino, A., Morgante, G., Baldini, D., Papaleo, E., Ragusa, G., Aversa, A., and Allegra, A. (2025). Diagnosis and Management of Infertility in Patients with Polycystic Ovary Syndrome (PCOS): Guidelines from the Italian Society of Human Reproduction (SIRU) and the Italian Centers for the Study and Conservation of Eggs and Sperm (CECOS Italy). Reprod. Biol. Endocrinol., 23.","DOI":"10.1186\/s12958-025-01372-5"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/aogs.14725","article-title":"International Evidence-Based Guideline on Assessment and Management of PCOS\u2014A Nordic Perspective","volume":"103","author":"Forslund","year":"2024","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, A.S., Witchel, S.F., Boivin, J., Burgert, T.S., Ee, C., Hoeger, K.M., Lujan, M.E., Mousa, A., Oberfield, S., and Tay, C.T. (2025). International Evidence-Based Recommendations for Polycystic Ovary Syndrome in Adolescents. BMC Med., 23.","DOI":"10.1186\/s12916-025-03901-w"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e11010","DOI":"10.1016\/j.heliyon.2022.e11010","article-title":"An Update of Polycystic Ovary Syndrome: Causes and Therapeutics Options","volume":"8","author":"Matani","year":"2022","journal-title":"Heliyon"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2042018810380215","article-title":"Review: Role of Metformin in the Management of Polycystic Ovary Syndrome","volume":"1","author":"Lashen","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome","volume":"120","author":"Teede","year":"2023","journal-title":"Fertil. Steril."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/17446651.3.3.349","article-title":"Treatment for Polycystic Ovary Syndrome: A Critical Appraisal of Treatment Options","volume":"3","author":"Nader","year":"2008","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1210\/jc.2013-2374","article-title":"Adverse Effects of the Common Treatments for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis","volume":"98","author":"Domecq","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"The Practice Committee of the American Society for Reproductive Medicine (2013). Use of Clomiphene Citrate in Infertile Women: A Committee Opinion. Fertil. Steril., 100, 341\u2013348.","DOI":"10.1016\/j.fertnstert.2013.05.033"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s13224-012-0183-3","article-title":"Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study","volume":"62","author":"Sangeeta","year":"2012","journal-title":"J. Obstet. Gynecol. India"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., and Meczekalski, B. (2023). Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185915"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0974-1208.147492","article-title":"Orlistat in Polycystic Ovarian Syndrome Reduces Weight with Improvement in Lipid Profile and Pregnancy Rates","volume":"7","author":"Kumar","year":"2014","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13224-018-1140-6","article-title":"Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials","volume":"68","author":"Panda","year":"2018","journal-title":"J. Obstet. Gynecol. India"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"The Practice Committee of the American Society for Reproductive Medicine (2006). Use of Clomiphene Citrate in Women. Fertil. Steril., 86, S187\u2013S193.","DOI":"10.1016\/j.fertnstert.2006.08.023"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0015-0282(16)48072-6","article-title":"Antiestrogenic Effect of Clomiphene Citrate Correlation with Serum Estradiol Concentrations","volume":"42","author":"Maxson","year":"1984","journal-title":"Fertil. Steril."},{"key":"ref_42","first-page":"CD010287","article-title":"Aromatase Inhibitors (Letrozole) for Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome","volume":"9","author":"Franik","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Singh, S., Pal, N., Shubham, S., Sarma, D.K., Verma, V., Marotta, F., and Kumar, M. (2023). Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041454"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10815-022-02429-9","article-title":"The Use of Metformin in Women with Polycystic Ovary Syndrome: An Updated Review","volume":"39","author":"Notaro","year":"2022","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2605.2005.00623.x","article-title":"Development of Polycystic Ovary Syndrome: Involvement of Genetic and Environmental Factors","volume":"29","author":"Franks","year":"2006","journal-title":"Int. J. Androl."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Froldi, G. (2024). View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040478"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13300-021-01058-2","article-title":"Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis","volume":"12","author":"Grant","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wu, H.-M., Chang, H.-M., and Leung, P.C.K. (2021). Gonadotropin-Releasing Hormone Analogs: Mechanisms of Action and Clinical Applications in Female Reproduction. Front. Neuroendocrinol., 60.","DOI":"10.1016\/j.yfrne.2020.100876"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tem.2023.02.002","article-title":"Gonadotropins as Pharmacological Agents in Assisted Reproductive Technology and Polycystic Ovary Syndrome","volume":"34","author":"Singh","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gullo, G., Cucinella, G., Stojanovic, V., Stojkovic, M., Bruno, C., Streva, A.V., Lopez, A., Perino, A., and Marinelli, S. (2024). Ovarian Hyperstimulation Syndrome (OHSS): A Narrative Review and Legal Implications. J. Pers. Med., 14.","DOI":"10.3390\/jpm14090915"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cen.14913","article-title":"Combined Oral Contraceptive Pill Compared with No Medical Treatment in the Management of Polycystic Ovary Syndrome: A Systematic Review","volume":"99","author":"Forslund","year":"2023","journal-title":"Clin. Endocrinol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","article-title":"Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study","volume":"98","author":"Ganie","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic Effect of Spirolactones: Mechanism of Action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijwd.2020.05.002","article-title":"Retrospective Analysis of Adverse Events with Spironolactone in Females Reported to the United States Food and Drug Administration","volume":"6","author":"Wang","year":"2020","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/bdr2.1799","article-title":"Risk Management of Teratogenic Medicines: A Systematic Review","volume":"112","author":"Shroukh","year":"2020","journal-title":"Birth Defects Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12978-021-01073-3","article-title":"Impact of Myo-Inositol Treatment in Women with Polycystic Ovary Syndrome in Assisted Reproductive Technologies","volume":"18","author":"Merviel","year":"2021","journal-title":"Reprod. Health"},{"key":"ref_57","first-page":"CD012378","article-title":"Inositol for Subfertile Women with Polycystic Ovary Syndrome","volume":"12","author":"Showell","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/CLEP.S311785","article-title":"Genetically Predicted Cigarette Smoking in Relation to Risk of Polycystic Ovary Syndrome","volume":"13","author":"Tao","year":"2021","journal-title":"Clin. Epidemiol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wojciechowska, A., Osowski, A., J\u00f3\u017awik, M., G\u00f3recki, R., Rynkiewicz, A., and Wojtkiewicz, J. (2019). Inositols\u2019 Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225787"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/2665978602666210805092103","article-title":"A Detailed Review on Herbal Treatments for Treatment of PCOS- Polycystic Ovary Syndrome (PCOS)","volume":"2","author":"Wal","year":"2021","journal-title":"Curr. Nutraceuticals"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ee, C., Pirotta, S., Mousa, A., Moran, L., and Lim, S. (2021). Providing Lifestyle Advice to Women with PCOS: An Overview of Practical Issues Affecting Success. BMC Endocr. Disord., 21.","DOI":"10.1186\/s12902-021-00890-8"},{"key":"ref_62","first-page":"CD007506","article-title":"Lifestyle Changes in Women with Polycystic Ovary Syndrome","volume":"3","author":"Lim","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shahid, R., Awan, K.A., Iqbal, M.J., Munir, H., and Saeed, I. (2022). Diet and Lifestyle Modifications for Effective Management of Polycystic Ovarian Syndrome (PCOS). J. Food Biochem., 46.","DOI":"10.1111\/jfbc.14117"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cowan, S., Lim, S., Alycia, C., Pirotta, S., Thomson, R., Gibson-Helm, M., Blackmore, R., Naderpoor, N., Bennett, C., and Ee, C. (2023). Lifestyle Management in Polycystic Ovary Syndrome\u2014Beyond Diet and Physical Activity. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-022-01208-y"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/09513590.2015.1101440","article-title":"The Amount and Duration of Smoking Is Associated with Aggravation of Hormone and Biochemical Profile in Women with PCOS","volume":"32","author":"Xirofotos","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1093\/humrep\/deu239","article-title":"Smoking in Infertile Women with Polycystic Ovary Syndrome: Baseline Validation of Self-Report and Effects on Phenotype","volume":"29","author":"Legro","year":"2014","journal-title":"Hum. Reprod. Oxf. Engl."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Unfer, V., Russo, M., Aragona, C., Bilotta, G., Montanino Oliva, M., and Bizzarri, M. (2023). Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes. Biomedicines, 11.","DOI":"10.3390\/biomedicines11061759"},{"key":"ref_68","first-page":"508","article-title":"Efficacy of Myo-Inositol in the Treatment of Cutaneous Disorders in Young Women with Polycystic Ovary Syndrome","volume":"25","author":"Caputo","year":"2009","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1849162","DOI":"10.1155\/2016\/1849162","article-title":"Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials","volume":"2016","author":"Unfer","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"A925","DOI":"10.1016\/j.jval.2017.08.3099","article-title":"Evaluating Community Pharmacists\u2019 Response To Adverse Drug Events Among Women With Pcos: A Simulated-Client Study","volume":"20","author":"Ibrahim","year":"2017","journal-title":"Value Health"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jval.2018.07.449","article-title":"Polycystic Ovarian Syndrome: Perception of Women with Pcos and Impact of Pharmacist\u2019s Intervention","volume":"21","author":"Ravi","year":"2018","journal-title":"Value Health"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jep.13310","article-title":"Assessing the Effectiveness of a Pharmaceutical Care Service on the Quality of Life of Women with Polycystic Ovarian Syndrome Living in War and Non-War Countries","volume":"26","author":"Alkoudsi","year":"2020","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.sapharm.2019.08.027","article-title":"Prevalence of Anxiety and Depression among Women with Polycystic Ovary Syndrome Living in War versus Non-War Zone Countries: A Randomized Controlled Trial Assessing a Pharmacist Intervention","volume":"16","author":"Alkoudsi","year":"2020","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.fertnstert.2009.11.001","article-title":"Lifestyle Management Improves Quality of Life and Depression in Overweight and Obese Women with Polycystic Ovary Syndrome","volume":"94","author":"Thomson","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_75","first-page":"E206","article-title":"Dietary Supplements for Polycystic Ovary Syndrome","volume":"63","author":"Kiani","year":"2022","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Han, Y., Hou, Y., Han, Q., Yuan, X., and Chen, L. (2024). Dietary Supplements in Polycystic Ovary Syndrome\u2013Current Evidence. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1456571"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0042-1748036","article-title":"Contraception for Women with Polycystic Ovary Syndrome: Dealing with a Complex Condition","volume":"44","author":"Spritzer","year":"2022","journal-title":"Rev. Bras. Ginecol. E Obstetr\u00edcia RBGO Gynecol. Obstet."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Szymczak-Pajor, I., Drzewoski, J., Wenclewska, S., and \u015aliwi\u0144ska, A. (2024). Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070898"},{"key":"ref_79","first-page":"e44493","article-title":"Role of Metformin in Polycystic Ovary Syndrome (PCOS): Related Infertility","volume":"15","author":"Attia","year":"2023","journal-title":"Cureus"},{"key":"ref_80","first-page":"599","article-title":"Potential Drug Interactions in Patients Taking Oral Contraceptive Pills","volume":"100","author":"Tsabai","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mce.2012.10.029","article-title":"Longterm Management of Polycystic Ovarian Syndrome (PCOS)","volume":"373","author":"Bates","year":"2013","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/4\/95\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:08:46Z","timestamp":1760033326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/4\/95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["pharmacy13040095"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13040095","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}